Latest Regulatory Approval News

Cobram Estate Olives reported a widened half-year loss driven by higher oil costs and operating expenses, while progressing its US growth strategy with a major California acquisition.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Qube Holdings reported a robust half-year performance for FY26, with underlying revenue climbing 12.9% and a significant property sale boosting statutory profits. The company also announced a major acquisition agreement with Macquarie Asset Management, signaling a transformative phase ahead.

Li-S Energy narrows its loss to $1.21 million in H1 2026, propelled by a $7.8 million ARENA grant and key manufacturing milestones including Australia’s first lithium metal foil production line. Strategic defence and aerospace partnerships bolster its commercialisation drive.

Reef Casino Trust has reported a 4.8% increase in revenue and a 6.4% rise in net profit for 2025, supported by strong casino and hotel performance. Meanwhile, a takeover bid at $3.87 per unit is underway, backed by major unitholders and recommended by the board.

Rio Tinto reported solid 2025 results with an 8% increase in copper equivalent production and disciplined cost management, driving a 9% rise in underlying EBITDA to $25.4 billion. The company marked major project completions and maintained a strong dividend payout.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

4DS Memory Limited has responded to an ASX price query following a notable rise in its share price and trading volume, confirming no undisclosed information but highlighting ongoing strategic discussions in AI-related technology.

Alcidion has secured regulatory approval for its AI-powered clinical tool in Australia and the UK, paving the way for commercial rollout in its largest markets. This milestone strengthens its position in healthcare technology and opens new sales avenues.

BPH Global is nearing completion of its novel seaweed-based men’s health supplement, Project Popeye, as it moves toward TGA listing and scientific validation.

Australian Vanadium Limited has broadened its Optimised Feasibility Study to include high purity vanadium products aimed at aerospace, defence, and advanced manufacturing sectors, aligning with evolving critical minerals demand without delaying project timelines.

Zip Co has delivered a standout half-year performance with record cash earnings and upgraded FY26 guidance, driven by strong US market momentum and innovative product launches.